What SEC filings does Ionis Pharmaceuticals, Inc. submit to the SEC?

Ionis Pharmaceuticals, Inc. (IONS) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about IONS?

A Form 4 for IONS discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Ionis Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for IONS?

The 10-K is Ionis Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all IONS SEC filings directly on EDGAR?

You can view all historical Ionis Pharmaceuticals, Inc. filings on the SEC EDGAR company page for IONS. Each filing card on this page links directly to the original SEC document.

How often does Ionis Pharmaceuticals, Inc. file with the SEC?

Ionis Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling IONS shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

IONS SEC Filing News — Ionis Pharmaceuticals, Inc.

Latest SEC filings for Ionis Pharmaceuticals, Inc. (IONS) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-16.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult pat…

Sector: Healthcare Industry: Biotechnology Market Cap: $7.4B CIK: 874015

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for IONS currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

IONS Filing Activity Snapshot 2026-07-09 — 2026-10-16

Insider Transactions (Form 4)

1 buy vs 3 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.74M

BENNETT C FRANK (EVP, Chief Scientific Officer) · 2026-07-09

20,536 shares · Form 4

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Ionis Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 4 other reported transaction, 3 open-market sale, 2 compensation award, 2 option exercise and 1 open-market purchase. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Other reported transaction ×4: The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.
Open-market sale ×3: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Option exercise ×2: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Other reported transaction Tax / Compensation Filing 2026-09-02

IONS insider Form 4 filed for equity award, exercise, or tax withholding

BENNETT C FRANK (EVP, Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	110	$51.31	$5.6K

Filing: Form 4 (Insider Transaction) Insider: BENNETT C FRANK (EVP, Chief Scientific Officer) Shares: 110

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-09-02

IONS insider Form 4 filed for equity award, exercise, or tax withholding

O'NEIL PATRICK R. (EVP CLO & General Counsel) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	63	$51.31	$3.2K

Filing: Form 4 (Insider Transaction) Insider: O'NEIL PATRICK R. (EVP CLO & General Counsel) Shares: 63

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-09-02

IONS insider Form 4 filed for equity award, exercise, or tax withholding

Birchler Brian (EVP, Corp and Development Ops) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	58	$51.31	$3.0K

Filing: Form 4 (Insider Transaction) Insider: Birchler Brian (EVP, Corp and Development Ops) Shares: 58

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-09-02

IONS insider Form 4 filed for equity award, exercise, or tax withholding

Monia Brett P (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	98	$51.31	$5.0K

Filing: Form 4 (Insider Transaction) Insider: Monia Brett P (Director, Chief Executive Officer) Shares: 98

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-07-31

IONS insider Hayden Michael R (Director) bought 20,000 shares (~$1.06M)

Hayden Michael R, listed as Director at IONIS PHARMACEUTICALS INC, reported an open-market purchase of 20,000 IONS shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	15,000	$53.38	$800.7K
`P`	Open-market purchase	5,000	$51.60	$258.0K

Filing: Form 4 (Insider Transaction) Insider: Hayden Michael R (Director) Shares: 20,000 Est. Value: $1.06M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

IONS insider Form 4 filed for equity award, exercise, or tax withholding

Reikes Peter N (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Restricted Stock Unit	3,399	—	—

Filing: Form 4 (Insider Transaction) Insider: Reikes Peter N (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-07-17

IONS insider Form 4 filed for equity award, exercise, or tax withholding

BERTHELSEN SPENCER R (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	5,220	—	—
`M`	Option exercise derivative · Restricted Stock Unit	5,220	—	—

Filing: Form 4 (Insider Transaction) Insider: BERTHELSEN SPENCER R (Director) Shares: 5,220

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-17

IONS insider Form 4 filed for equity award, exercise, or tax withholding

HANTSON LUDWIG (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Restricted Stock Unit	3,399	—	—

Filing: Form 4 (Insider Transaction) Insider: HANTSON LUDWIG (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-07-17

IONS insider Form 4 filed for equity award, exercise, or tax withholding

HERMAN JOAN E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	5,220	—	—
`M`	Option exercise derivative · Restricted Stock Unit	5,220	—	—

Filing: Form 4 (Insider Transaction) Insider: HERMAN JOAN E (Director) Shares: 5,220

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-09

IONS insider BENNETT C FRANK (EVP, Chief Scientific Officer) sold 20,536 shares (~$1.74M)

BENNETT C FRANK, listed as EVP, Chief Scientific Officer at IONIS PHARMACEUTICALS INC, reported an open-market sale of 20,536 IONS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	5,536	$83.58	$462.7K
`J`	Other transaction	15,000	—	—
`S`	Open-market sale	15,000	$85.46	$1.28M
`J`	Other transaction derivative · Restricted Stock Unit	15,000	—	—

Filing: Form 4 (Insider Transaction) Insider: BENNETT C FRANK (EVP, Chief Scientific Officer) Shares: 20,536 Est. Value: $1.74M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-09

IONS insider Diaz Allene M. (Director) sold 10,111 shares (~$863.6K)

Diaz Allene M., listed as Director at IONIS PHARMACEUTICALS INC, reported an open-market sale of 10,111 IONS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	10,111	$47.11	$476.3K
`S`	Open-market sale	10,111	$85.42	$863.6K
`M`	Option exercise derivative · Non-Qualified Stock Option (right to buy)	10,111	—	—

Filing: Form 4 (Insider Transaction) Insider: Diaz Allene M. (Director) Shares: 10,111 Est. Value: $863.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-09

IONS insider Kordasiewicz Holly B. (EVP, Chief Development Officer) sold 362 shares (~$30.5K)

Kordasiewicz Holly B., listed as EVP, Chief Development Officer at IONIS PHARMACEUTICALS INC, reported an open-market sale of 362 IONS shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	362	$84.30	$30.5K

Filing: Form 4 (Insider Transaction) Insider: Kordasiewicz Holly B. (EVP, Chief Development Officer) Shares: 362 Est. Value: $30.5K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Ionis Pharmaceuticals, Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-16

IONS Form 144 filed for proposed insider sale by Devers Shannon L. (1,357 shares) ~$59.7K

Devers Shannon L. filed a Form 144 with the SEC indicating intent to sell IONS (IONIS PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Devers Shannon L. Shares: 1,357 Est. Value: $59.7K

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Ionis Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-23